Articles tagged "Kidney transplantation"

2020 American Transplant Congress
Impact of Extracorporeal Photopheresis in a Full-Mismatch Kidney Transplant Rat Model
J. Rovira¹, G. J. Piñeiro², M. Lazo-Rodriguez³, M. J. Ramirez-Bajo¹, E. Banon-Maneus³, N. Hierro-Garcia³, P. Ventura-Aguiar², J. Cid⁴, M. Lozano⁴, F. Diekmann²
¹Laboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS, Barcelona, Spain, ²Department of Nephrology and Renal Transplantation, Hospital Clínic de Barcelona, Barcelona, Spain, ³Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Fundació Clínic per la Recerca Biomèdica (FCRB), Barcelona, Spain, ⁴Apheresis Unit, Department of Hemotherapy and Hemostasis, Hospital Clínic de Barcelona, Barcelona, Spain
*Purpose: Extracorporeal photopheresis (ECP) is an immunomodulatory cell therapy based on the infusion of autologous cellular products exposed to ultraviolet light (UV), in the presence…
2020 American Transplant Congress
Effect of Low vs Standard Dosage of Anti-Thymocyte Globulin Induction Therapy on the Co-Inducible Molecules (Cd28, CTLA-4, ICOS, PD-1) Expression Pattern in T Regulatory Cell
G. Queipo¹, A. Hernandez-Mendoza¹, M. Estrada-Matus², M. Fonseca-Sanchez¹, F. Oviedo¹, L. García-Cobarruvias³, J. Prieto Chávez⁴, L. Pizarro⁵, L. Morales-Buenrostro⁶
¹Human Genetics, Hospital General de Mexico-Eduardo Liceaga Facultad de Medicina UNAM, Mexico City, Mexico, ²Nephrology, Instituno Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Transplant Unit, Hospital General de Mexico-Eduardo Liceaga, Mexico City, Mexico, ⁴Flow Cytometry Core, Mexican Social Security Institute, Mexico City, Mexico, ⁵Unit on Immunochemistry, Medical Research, Specialties Hospital of the National Medical Centre “SigloXXI”, Mexico City, Mexico, ⁶Nephrology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico
*Purpose: Two thymoglobulin (TG) dosages effect on the Tregulatory cell (Treg) and describe the behavior of the co-stimulatory pathways in terms of FIM and gene…
2020 American Transplant Congress
Improving DRG Based Reimbursement to Reflect Complexity of Kidney Transplant
I. R. Schwantes¹, M. Schnitzler², K. Lentine², A. Reed¹, D. A. Axelrod³
¹Surgery, University of Iowa, Iowa City, IA, ²Saint Louis University, St. Louis, MO, ³Surgery, Universtiy of Iowa, Iowa City, IA
*Purpose: More than 90,000 individuals await a kidney transplant (KTx) in the US, yet up to 20% of recovered kidneys are discarded. Organ Transplant Centers…
2020 American Transplant Congress
High Volume, Highly Efficient, Outcome- Centric KPD Program: A Single Center Experience with Direct Exchange Based Strategies
K. Al Meshari, D. Broering, I. Alahmadi, S. Raza, T. Ali, A. Alabbassi, H. Alahdal, F. Alzayer
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
*Purpose: We report our three and a half year experience with direct exchange (loop) based strategy single center KPD program.*Methods: 1. Inclusion of HLA and…
2020 American Transplant Congress
Belatacept-Based, Calcineurin Inhibitor and Corticosteroid Free Immunosuppression: Differential Outcomes Based on Recipient Age
N. Wilson¹, A. R. Shields², D. Kaufman³, A. Wiseman⁴, A. L. Christianson¹, S. Tremblay¹, J. P. Leone⁵, A. J. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²The Christ Hospital, Cincinnati, OH, ³U Wisconsin, Madison, WI, ⁴U Colorado, Denver, CO, ⁵Tampa General, Tampa, FL, ⁶U Minnesota, Minneapolis, MN, ⁷U Illinois Chicago, Chicago, IL
*Purpose: Age-based disparities have been described in calcineurin inhibitor (CNI)-based immunosuppression regimens, but are not well-described for belatacept (BELA)-based regimens. This study analyzed the effect…
2020 American Transplant Congress
Mortality Index Should Be Used to Provide Realistic Expectations Regarding Transplant Candidacy
Y. Chalicheemala¹, K. Chavin², T. Srinivas¹, A. Padiyar¹
¹Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, ²Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH
*Purpose: Renal transplant improves outcomes of well-selected elderly patients with end stage renal disease. Older patients with significant comorbidities may not live long enough to…
2020 American Transplant Congress
TRANSBIO Study: Clinical Evaluation of Immunobiogram, a Novel In Vitro Diagnostic Immunoassay to Guide Adjustment of Immunosuppressive Therapy in Kidney Transplantation
J. Pascual¹, C. Jiménez², M. Krajewska³, C. Kotton⁴, D. Seron⁵, J. Portolés⁶, O. Witzke⁷, S. S. Sorensen⁸, A. Andrés⁹, T. Díez¹⁰, A. Ortega¹⁰, I. Portero¹⁰
¹Consorci Mar Parc de Salut, Barcelona, Spain, ²La Paz Hospital, Madrid, Spain, ³Wroclaw Medical University, Wroclaw, Poland, ⁴Massachusetts General Hospital, Boston, MA, ⁵Vall d’Hebron Hospital, Barcelona, Spain, ⁶Puerta de Hierro Mahadahonda Hospital, Madrid, Spain, ⁷University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁸Rigshospitalet, Copenhagen, Denmark, ⁹12 de Octubre Hospital, Madrid, Spain, ¹⁰Biohope Scientific Solutions for Human Health SL, Madrid, Spain
*Purpose: Immunobiogram (IMBG) is a first-in-class blood-based pharmacodynamic immunoassay that provides the sensitivity/resistance profile of each patient’s lymphocytes to a panel of immunosuppressive drugs (IS).…
2020 American Transplant Congress
Clinical Significance of T Cell and B Cell Epitope Prediction as a Risk Factor of De Novo DSA Production after Kidney Transplantation
T. Kobayashi¹, K. Iwasaki¹, T. Tomosugi², Y. Miwa¹, M. Niemann³, E. Spierings⁴, K. Horimi¹, Y. Matsuoka¹, A. Takeda², N. Goto², S. Narumi², Y. Watarai²
¹Aichi Medical University School of Medicine, Nagakute, Japan, ²Nagoya Daini Red Cross Hospital, Nagoya, Japan, ³PIRCHE AG, Berlin, Germany, ⁴UMC Utrecht, Utrecht, Netherlands
*Purpose: Chronic antibody-mediated rejection caused by de novo DSA (dnDSA) is a major cause of graft failure. Risk prediction of dnDSA would be important for…
2020 American Transplant Congress
Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys
V. S. Potluri¹, F. Naqvi², P. Reese¹, M. Shah¹, D. Brown², S. Prenner¹, A. Loupy³, A. Woodards¹, P. Abt¹, E. Blumberg¹, J. Trofe-Clark¹, D. Segev², R. Bloom¹, D. Sawinski¹, C. Durand², P. Porrett¹, M. Levine¹, D. Goldberg⁴, N. Desai²
¹University of Pennsylvania, Philadelphia, PA, ²Johns Hopkins, Baltimore, MD, ³Paris Transplant Group, Paris, France, ⁴University of Miami, Miami, FL
*Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on…
2020 American Transplant Congress
Outcomes Associated with Mycophenolate Weight-Based Dosing in Varying Immunologic Risk Kidney Transplant Recipients
A. A. Al-Bahou, A. R. Webb, M. Bloxam, L. J. Bowman Anger, R. S. Baliga, A. J. Brueckner
Tampa General Hospital, Tampa, FL
*Purpose: Mycophenolate acid (MPA) is traditionally dosed in kidney transplant recipients (KTR) using the FDA-approved fixed dosing which is irrespective of patient-specific variables such as…